What is DotLab?
DotLab is at the forefront of women's healthcare innovation, specializing in the development of advanced diagnostic technologies. Its flagship product, DotEndo, is a non-invasive blood test designed to aid in the diagnosis of active endometriosis. By measuring specific biomarkers, DotEndo offers a crucial tool for identifying the disease across all stages, irrespective of hormonal cycles or symptom presentation. This technology aims to drastically reduce the diagnostic timeline, which historically averages over eleven years, by providing clinicians and patients with actionable insights for earlier intervention and treatment. DotLab's mission is to bridge a significant diagnostic gap in women's health, particularly for individuals facing unexplained infertility.
How much funding has DotLab raised?
DotLab has raised a total of $10M across 1 funding round:
Series A
$10M
Series A (2019): $10M with participation from CooperSurgical, TriplePoint Venture Growth BDC, Luxor Capital Group, and Wilson Sonsini Goodrich & Rosati
Key Investors in DotLab
CooperSurgical
CooperSurgical is a key participant in this funding round, likely contributing strategic expertise in surgical and medical devices for women's health.
TriplePoint Venture Growth BDC
TriplePoint Venture Growth BDC, a venture growth stage financier, provides capital to high-growth companies, indicating DotLab's strong potential for scaling and market expansion.
Luxor Capital Group
Luxor Capital Group, a financial services firm specializing in investment management, likely brings sophisticated financial strategies and support for DotLab's growth trajectory.
What's next for DotLab?
With the recent infusion of major strategic capital, DotLab is poised for accelerated growth and market penetration. The company's focus on a critical unmet need in women's health, coupled with its groundbreaking diagnostic technology, positions it for significant expansion. Future endeavors will likely involve scaling its commercial operations, further research and development to enhance its diagnostic capabilities, and forging strategic partnerships within the healthcare ecosystem. This substantial backing from investors indicates confidence in DotLab's potential to revolutionize endometriosis diagnosis and improve patient outcomes globally.
See full DotLab company page
